Protein Kinase C (PKC)-α Activation Inhibits PKC-ζ and Mediates the Action of PED/PEA-15 on Glucose Transport in the L6 Skeletal Muscle Cells
- Gerolama Condorelli,
- Giovanni Vigliotta,
- Alessandra Trencia,
- Maria Alessandra Maitan,
- Matilde Caruso,
- Claudia Miele,
- Francesco Oriente,
- Stefania Santopietro,
- Pietro Formisano and
- Francesco Beguinot
- Dipartimento di Biologia e Patologia Cellulare e Molecolare and the Centro di Endocrinologia ed Oncologia Sperimentale del C.N.R., Federico II University of Naples, Naples, Italy
Abstract
Overexpression of the PED/PEA-15 protein in muscle and adipose cells increases glucose transport and impairs further insulin induction. Like glucose transport, protein kinase C (PKC)-α and -β are also constitutively activated and are not further stimulatable by insulin in L6 skeletal muscle cells overexpressing PED (L6PED). PKC-ζ features no basal change but completely loses insulin sensitivity in L6PED. In these cells, blockage of PKC-α and -β additively returns 2-deoxy-d-glucose (2-DG) uptake to the levels of cells expressing only endogenous PED (L6WT). Blockage of PKC-α and -β also restores insulin activation of PKC-ζ in L6PED cells, with that of PKC-α sixfold more effective than PKC-β. Similar effects on 2-DG uptake and PKC-ζ were also achieved by 50-fold overexpression of PKC-ζ in L6PED. In L6WT, fivefold overexpression of PKC-α or -β increases basal 2-DG uptake and impairs further insulin induction with no effect on insulin receptor or insulin receptor substrate phosphorylation. In these cells, overexpression of PKC-α blocks insulin induction of PKC-ζ activity. PKC-β is 10-fold less effective than PKC-α in inhibiting PKC-ζ stimulation. Expression of the dominant-negative K281→W PKC-ζ mutant simultaneously inhibits insulin activation of PKC-ζ and 2-DG uptake in the L6WT cells. We conclude that activation of classic PKCs, mainly PKC-α, inhibits PKC-ζ and may mediate the action of PED on glucose uptake in L6 skeletal muscle cells.
Footnotes
-
Address correspondence and reprint requests to Francesco Beguinot, MD, PhD, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli Federico II, Via S. Pansini 5, 80131 Naples, Italy. E-mail: beguino{at}unina.it.
Received for publication 15 August 2000 and accepted in revised form 22 February 2001.
G.C. and G.V. contributed equally to this article.
2-DG, 2-deoxy-d-glucose; DAG, diacylglycerol; DMEM, Dulbecco’s modified Eagle’s medium; ECL, enhanced chemiluminescence; IRS, insulin receptor substrate; PI, phosphatidylinositol; PKB, protein kinase B; PKC, protein kinase C; PMSF, phenylmethylsulfonyl fluoride; TPA, 12-O-tetradecanoylphorbol-13-acetate.














